I-Mab (IMAB)

NASDAQ: IMAB · Delayed Price · USD
12.06
-0.64 (-5.04%)
At close: May 18, 2022 4:00 PM
12.15
0.09 (0.75%)
After-hours:May 18, 2022 7:37 PM EDT
Market Cap996.71M
Revenue (ttm)13.75M
Net Income (ttm)-364.30M
Shares Out82.65M
EPS (ttm)-4.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,015,101
Open12.23
Previous Close12.70
Day's Range11.98 - 12.68
52-Week Range10.14 - 85.40
Beta0.82
AnalystsBuy
Price Target87.37 (+624.5%)
Earnings DateMar 29, 2022

About IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and O...

IndustryBiotechnology
IPO DateJan 17, 2020
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolIMAB
Full Company Profile

Financial Performance

Financial numbers in millions CNYFinancial Statements

Analyst Forecast

According to 22 analysts, the average rating for IMAB stock is "Buy." The 12-month stock price forecast is 87.37, which is an increase of 624.46% from the latest price.

Price Target
$87.37
(624.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md. , May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and comm...

2 weeks ago - PRNewsWire

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

-  Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO -  Renowned oncology expert Dr. John Hayslip to further a...

Other symbols:NKTR
2 weeks ago - PRNewsWire

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

SHANGHAI and GAITHERSBURG, Md. , March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializ...

1 month ago - PRNewsWire

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab Seven business dev...

1 month ago - PRNewsWire

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

2 months ago - PRNewsWire

Why I-Mab Shares Are Jumping Today

I-Mab (NASDAQ: IMAB) has provided updates on the recent development relating to the Holding Foreign Companies Accountable Act (HFCAA) and its implementation.  I-Mab is not on this list, and it has taken...

2 months ago - Benzinga

I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and c...

2 months ago - PRNewsWire

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

2 months ago - PRNewsWire

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Tre...

SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

2 months ago - PRNewsWire

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biolog...

SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

3 months ago - PRNewsWire

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients ...

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

4 months ago - PRNewsWire

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD ., Jan. 1...

4 months ago - PRNewsWire

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembroliz...

SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

4 months ago - PRNewsWire

I-Mab Announces Senior Management Team Share Purchase Plan

SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializati...

4 months ago - PRNewsWire

I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?

I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

4 months ago - Zacks Investment Research

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

4 months ago - PRNewsWire

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembroli...

SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializat...

4 months ago - PRNewsWire

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Comme...

-  New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization  -  Dr. Andrew Zhu, an internationally renowned oncologist, appointed as P...

4 months ago - PRNewsWire

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

SHANGHAI and GAITHERSBURG, Md., Dec. 15, 2021 /PRNewswire/ -- I-Mab  (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercializa...

5 months ago - PRNewsWire

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Ho...

SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

5 months ago - PRNewsWire

I-Mab to Hold Investor Call to Present In-depth Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-H...

SHANGHAI and GAITHERSBURG, Md., Dec. 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease

SHANGHAI and GAITHERSBURG, Md., Dec. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

SHANGHAI and GAITHERSBURG, Md. , Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializati...

5 months ago - PRNewsWire

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patien...

SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializatio...

5 months ago - PRNewsWire

Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?

The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

6 months ago - Zacks Investment Research